Navigation Links
R-Tech Ueno Completes Subject Enrollment in Phase 2 Clinical Study of 0.15% UF-021
Date:8/24/2009

TOKYO, Aug. 25 /PRNewswire/ -- We are pleased to announce that subject enrollment for the phase 2 clinical study of 0.15% UF-021 (generic name; isopropyl unoprostone; active ingredient of Rescula(R) eye-drops) in patients with retinitis pigmentosa has been completed.

We submitted the notification of the clinical trial in August 2008. Enrollment in the phase 2 study began at six clinical sites in late December 2008 and was completed on August 3, 2009.

The clinical study has progressed with no delay, no serious adverse effects, and only a few cases of discontinuation so far. Hereafter, we expect to complete the study by next spring, including data collection and analysis.

Retinitis pigmentosa is a progressive hereditary disease affecting nearly 50,000 people in Japan, which is characterized by night blindness. Patients generally suffer from peripheral visual field loss and low vision in the late stage of the disease. At present, there is no effective treatment for this disease.

We developed and launched isopropyl unoprostone eye-drops on the market as a drug for glaucoma and ocular hypertension in 1994. In recent studies on isopropyl unoprostone, the drug has been reported to present neuroprotective effects and a function to improve ocular circulation. Studies at some university hospitals have also suggested that isopropyl unoprostone eye-drops improve symptoms of retinitis pigmentosa or stop the progression of the disease.

We expect isopropyl unoprostone to become a unique drug for improvement of the quality of vision in patients with retinitis pigmentosa.

About R-Tech Ueno, Ltd.

R-Tech Ueno was established in September 1989 for the purpose of marketing and R&D of drugs. Under the leadership of the president, also a medical doctor, the company is developing new drugs on the theme "Physician-Oriented New Drug Innov
'/>"/>

SOURCE R-Tech Ueno, Ltd.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine technology :

1. R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023
2. ProUroCare Medical Completes Clinical Trial at Second Study Site Using Digital Prostate Imaging Technology
3. SIRO Clinpharm Completes Successful Implementation of Oracle Life Sciences Application Suite
4. Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
5. Osteotech Completes Enrollment for DuraTech(TM) BioRegeneration Matrix Clinical Trial
6. Novavax Completes Enrollment of Its Second Phase II Seasonal Influenza VLP Vaccine Clinical Trial
7. Potentia Pharmaceuticals POT-4 Drug Candidate for Age-Related Macular Degeneration Successfully Completes Phase I Clinical Trial - Prepares for Phase II
8. Peregrine Pharmaceuticals Completes Patient Enrollment in its Phase II Trial of Bavituximab Plus Docetaxel in Breast Cancer Patients
9. QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
10. Major Restless Legs Study Completes Enrollment With Support From MediciGlobal
11. QuatRx Completes Enrollment of Ophena(TM)(Ospemifene Tablets) Final Pivotal Phase 3 Study in Women with Postmenopausal Vaginal Atrophy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2010)... Feb. 9 Echo Therapeutics, Inc. (OTC ... tCGM System as a non-invasive, wireless, transdermal continuous glucose ... transdermal drug delivery, announced today that Patrick T. ... be interviewed on " Steve Crowley ,s American Scene ... at 9:34 AM ET and Thursday, ...
(Date:2/9/2010)... Feb. 9 The rapid increase of ... to the CRO and CMO businesses there. However, DS ... manufacturing organization that focuses on fine and pharmaceutical chemicals, ... not only low costs," said Dr. Aaron Shen ... "What makes Chemphy so attractive to our customers? The ...
(Date:2/9/2010)... Delcath Systems, Inc. ( ... its proprietary treatment system for primary and metastatic ... of its first research, distribution, sales and marketing ...  (the Delcath PHP System™).  The agreement grants Chi-Fu ... and sell the Delcath PHP System in ...
Breaking Medicine Technology:Echo Therapeutics Chairman and CEO to be Interviewed on Steve Crowley's American Scene Radio Program and Featured on Money Channel Inc. 2Echo Therapeutics Chairman and CEO to be Interviewed on Steve Crowley's American Scene Radio Program and Featured on Money Channel Inc. 3Echo Therapeutics Chairman and CEO to be Interviewed on Steve Crowley's American Scene Radio Program and Featured on Money Channel Inc. 4DS Chemphy Focusing on CRO/CMO Business 2Delcath Signs First Partner Agreement in Asia 2Delcath Signs First Partner Agreement in Asia 3Delcath Signs First Partner Agreement in Asia 4Delcath Signs First Partner Agreement in Asia 5New book teaches core skills needed to create professional scientific communications 10155 1New book teaches core skills needed to create professional scientific communications 10155 2New book teaches core skills needed to create professional scientific communications 10155 3Telltale moss 10152 1Fetal Surgery May Treat Heart Defect 58458 1Fetal Surgery May Treat Heart Defect 58458 2Fetal Surgery May Treat Heart Defect 58458 3
(Date:2/9/2010)... pressure restrict fetal growth, study finds, , , TUESDAY, Feb. ... into pregnancy can have lasting effects on your baby,s ... that women who smoked, had high blood pressure or ... that were smaller in the first trimester of pregnancy ... "Our study demonstrates that several maternal physical characteristics and ...
(Date:2/9/2010)... Solution,: Selling Policies That Amount To ,A Cardboard Box ... Feb. 9 Blue Cross has ... premium hikes of up to 39% in California ... from the White House and an investigation by ... act to regulate health insurance premiums and force insurers ...
(Date:2/9/2010)... The following statement is attributable ... President, American Medical Association: ,, (Logo: ... Association is pleased to support First Lady ... Move Campaign. As the nation,s largest physician ... obesity and are committed to reenergizing our ...
(Date:2/9/2010)... Institute and the Sanford-Burnham Medical Research Institute have ... owned member of the Roche group, and Roche, ... develop and market human monoclonal antibodies to treat ... viruses include the strains for the current seasonal ... a non-exclusive right to manufacture, develop and market ...
(Date:2/9/2010)... in captivity primarily for their skins, but some restaurants ... A study shows that eating these animals can have ... eating this ,delicacy., , Parasites, bacteria and viruses, and ... residues of veterinary drugs- eating reptile meat can cause ... a study published in the International Journal of ...
Breaking Medicine News(10 mins):Health News:Mom's Lifestyle in Early Pregnancy Affects Baby's Size 2Health News:Mom's Lifestyle in Early Pregnancy Affects Baby's Size 3Health News:Blue Cross Claim That 39% Premium Hikes Due Only to 'Escalating Cost of Health Care' Trigger Calls for Regulation of Rates 2Health News:Blue Cross Claim That 39% Premium Hikes Due Only to 'Escalating Cost of Health Care' Trigger Calls for Regulation of Rates 3Health News:Study carried out into biological risks of eating reptiles 2
... soon be replaced by a pill according to European ... the effectiveness of the Grazax allergen tablet.// Hay fever ... shots. ,Allergies are a result of the immune ... dust mites. ,Immunotherapy is supposed to enhance ...
... of Carbohydrate Response Element Binding Protein (ChREBP) results in ... prevention of// normally obese mice from becoming fat. This ... University of Texas, Katsumi Iizuka, Bonnie Miller and Kosaku ... ,They discovered the important role played by ...
... arthritis (RA) patients have an increased risk of developing ... a lot of joint pain does have the risk ... including tumor necrosis factor alpha (TNFá) antagonists, a type ... ,TNF blockers, which work by attaching to ...
... the findings of a UCSF study to be published ... and Gynecology," the risk of miscarriage in pregnant women ... chromosomal abnormalities is lower than previously believed. ,Two ... tests performed during the first and second trimester of ...
... weakens. According to researchers, anger and hostility can aggravate this process.// ... – 86 years old. It was found that men who had ... had notably poorer lung function at the end of it. ... that hostility is associated with poorer pulmonary function and more rapid ...
... best friend, could turn out to be the worst ... worsen asthmatic children’s response to air pollution says a ... the connection between chronic cough, phlegm production (bronchitis) and ... McConnell, professor of preventive medicine at the University of ...
Other Medicine News:Health News:RA Drugs Not Implicated In Cancer 2Health News:Prenatal Test and Miscarriage 2Health News:Prenatal Test and Miscarriage 3Health News:Dogs aggravate asthma in kids 2
... for the treatment of presbyopia, a condition that ... older patients. , Presbyopia results from the gradual ... the eye as a person ages, making the ... the eye has a harder time focusing on ...
... forceps was designed by Joseph Kurstin, MD of ... the LASIK flap. It features disc-shaped tips ... the flap. Dr. Kurstin uses two forceps ... to straighten any micro striae. This stretching ...
... Piece Collamer lens, model CQ2015, combines the ... design. This lens contains a Collamer optic ... no angulation. These loops offer flexibility comparable ... tensile strength, and superior "shape memory". The ...
... has developed and patented a new, smaller and ... tomography (SPECT) with twice the resolution of existing ... an executive chair, runs on 110 Volts AC ... room without remodeling. The device has no visible ...
Medicine Products: